Johnson & Johnson (JNJ) to Issue Quarterly Dividend of $1.30 on December 9th

Johnson & Johnson (NYSE:JNJ) declared a quarterly dividend on Tuesday, October 14th, RTT News reports. Investors of record on Tuesday, November 25th will be paid a dividend of 1.30 per share on Tuesday, December 9th. This represents a c) dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th.

Johnson & Johnson has increased its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 64 consecutive years. Johnson & Johnson has a payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $11.07 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 47.0%.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $203.88 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50-day simple moving average of $188.25 and a two-hundred day simple moving average of $171.67. The firm has a market capitalization of $491.21 billion, a PE ratio of 19.68, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $206.94.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on JNJ. Scotiabank initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target on the stock. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.